|Day Low/High||33.40 / 34.02|
|52 Wk Low/High||28.25 / 37.39|
Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Medivation, Inc.
Pfizer Inc. (NYSE:PFE) today announced that it will be presenting data from 20 abstracts, including three late-breakers, at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen from October 7-11,...
Stocks end Monday's session sharply lower as Wall Street grows restless ahead of the first presidential debate.
Stocks hold near session lows by mid-afternoon Monday as Wall Street grows restless ahead of the first presidential debate.
The company has spent $600 million weighing a potential breakup.
Bernstein analysts say Pfizer (PFE) is likely to continue seeking M&As following the end of its planned business split.
Failure is very profitable for Pain Therapeutics CEO Remi Barbier.
Stocks are lower Monday as Wall Street's attention shifts to the looming presidential debate from central bank policy.
Shares of Pfizer were lower Monday after saying it will no longer pursue its plan to split into two publicly traded companies.
The company now believes that it makes more sense to keep its established drug and clinical products businesses under one roof.
U.S. stocks moved lower ahead of Monday's first presidential debate between Donald Trump and Hillary Clinton.
Stock futures fall on Monday as Wall Street's attention shifts from central bank policy to the looming presidential debate.
Pfizer (PFE) is abandoning a plan to split Pfizer Innovative Health and Pfizer Essential Health into two publicly traded companies.
Pfizer Inc. (NYSE:PFE) announced that, after an extensive evaluation, the company's Board of Directors and Executive Leadership Team have determined the company is best positioned to maximize future shareholder value...
Rumors are swirling about Big Pharma interest in the cancer drug developer, but the validity of such theories is questioned by at least some company followers.
Pfizer Inc. (NYSE: PFE) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended has expired with respect to Pfizer's pending acquisition of Medivation, Inc.
The board of directors of Pfizer Inc. today declared a 30-cent fourth-quarter 2016 dividend on the company's common stock, payable December 1, 2016, to shareholders of record at the close of business on November 11, 2016.
UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.
Pfizer Inc. (NYSE:PFE) announced the confirmatory study (REFLECTIONS B537-02) evaluating the efficacy, safety, and immunogenicity of PF-06438179 (infliximab-Pfizer) compared to Remicade® (infliximab) met its primary...
Given predictable upcoming catalysts and a large addressable market, this small-cap biotech is a buy.
Pfizer Inc. (NYSE:PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that IBRANCE ® (palbociclib) be...
FDA announcements and a price increase should be beneficial to these portfolio names.
Two FDA panels have recommended that it's most serious warning label be removed from the Pfizer (PFE) drug Chantix.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc.
Today, a joint meeting of the U.S.